Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Pembrolizumab/Vibostolimab	594
Overall Study	STARTED	Pembrolizumab	612
Overall Study	Treated	Pembrolizumab/Vibostolimab	593
Overall Study	Treated	Pembrolizumab	610
Overall Study	Received Pembrolizumab/Vibostolimab (MK-7684A) Second Course	Pembrolizumab/Vibostolimab	1
Overall Study	Received Pembrolizumab/Vibostolimab (MK-7684A) Second Course	Pembrolizumab	0
Overall Study	Received Pembrolizumab Second Course	Pembrolizumab/Vibostolimab	0
Overall Study	Received Pembrolizumab Second Course	Pembrolizumab	3
Overall Study	COMPLETED	Pembrolizumab/Vibostolimab	0
Overall Study	COMPLETED	Pembrolizumab	0
Overall Study	NOT COMPLETED	Pembrolizumab/Vibostolimab	594
Overall Study	NOT COMPLETED	Pembrolizumab	612

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04738487/flow